Please use this identifier to cite or link to this item:
|Title:||Prevalence of blood-borne viruses and hepatitis B vaccination status among haemodialysis patients in Central Australia.|
|Citation:||© 2022 The Authors.|
IJID Reg. 2022 Sep 27;5:111-116. doi: 10.1016/j.ijregi.2022.09.010. eCollection 2022 Dec.
|Abstract:||OBJECTIVE: A cross-sectional study to determine the prevalence of blood-borne viruses and hepatitis B vaccination status in haemodialysis patients in Central Australia. METHODS: Our study comprised 366 Aboriginal and 1 non-Indigenous Australian in Central Australia who had commenced haemodialysis between January 1996 and December 2019. RESULTS: Chronic hepatitis B infection was seen in 8.4% of patients, and serological evidence of human T-lymphotropic virus 1 in 28.3% of patients. The prevalence of HIV and hepatitis C was less than 1%. The vaccine status of all 182 patients who had received the hepatitis B vaccine was reviewed. Vaccine response was seen in 72.2% of patients who had received the vaccine at birth or in early childhood. There were 99 patients aged 20 years and older who had received hepatitis B vaccines before their haemodialysis commenced. Vaccine response was observed in 88.9% of these patients. A seroconversion rate of 78.5% was achieved in vaccine naïve patients who received the hepatitis B vaccine after their haemodialysis commenced. CONCLUSION: The response to the hepatitis B vaccine among haemodialysis patients in Central Australia was suboptimal and variable. The prevalence of chronic hepatitis B infection declined after the universal hepatitis B vaccination was introduced in 2000.|
|Click to open Pubmed Article:||https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/36277500|
|Journal title:||IJID Regions (Online)|
|Appears in Collections:||(a) NT Health Research Collection|
Files in This Item:
There are no files associated with this item.
Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.